The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer

Abstract

Abstract. Conclusion: The synergistic effect of vandetanib with 5-FU is related to vandetanib-induced reduction of TYMS via down-regulation of cyclin D1. Hyperexpression of cyclin D1 might be a biomarker of the synergistic effect.Gastric cancer is one of the most common malignant diseases worldwide, especially in the Asian countries (1). Although the expansion of multidisciplinary care, including advances in chemotherapeutic agents and surgical techniques, has progressed, gastric cancer is still a lifethreating malignancy as the second leading cause of cancer mortality (2). In patients with stages II (excluding T1 disease) or III (moderately advanced) gastric cancer, the recurrence rate is extremely high, at 41.7% after surgery alone, even with curative resection (3). Thus, chemotherapy is expected to improve the prognosis for advanced or recurrent gastric cancer. Among anticancer agents, 5-fluorouracil (5-FU) has been widely accepted for the treatment of gastric cancer and clinically represents the key drug. Indeed, current clinical trials have shown 5-FU to have a significant effect after surgery not only with single use (3, 4), but also in combination with cisplatin or docetaxel (5-8). However, in patients with unresectable or recurrent gastric cancer, the median survival time and 2-year survival rates are estimated to be 12.5-13.0 months and 22.9-23.6% (5, 6). In order to exert a stronger effect of chemotherapeutic agents, the drug-delivery system needs to be considered or metabolic factors need to be changed (9). The action of 5-FU depends on the presence of cellular thymidylate synthase (TYMS), which is one of the metabolic enzymes for 5-FU, and its growth-inhibitory effect is well-known to be affected 5215

The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin

“…Gastric cancer is one of the most common malignant diseases and the second leading cause of cancer-related deaths worldwide, especially in the Asian countries [ 1 ]. Despite great advances in surgical techniques and chemotherapeutic agents for gastric cancer, the 5-year-survival rate in patients is still unsatisfactory due to its metastasis and chemoresistance [ 2 , 3 ]. Therefore, it is indispensable to identify potential novel chemotherapy targets and understand their molecular mechanisms for improving the prognosis of gastric cancer.…”

Oxymatrine Synergistically Potentiates the Antitumor Effects of Cisplatin in Human Gastric Cancer Cells

“…GC is a serious threat to humans because of its high incidence and mortality 2 , and China got the highest incidence of GC 3 . Despite great advances made in surgical techniques and chemotherapeutic agents, the 5-year survival rate of patients with GC is still dissatisfaction due to lack of early diagnosis and chemo-resistance 4 , 5 . Therefore, new and safe strategies to overcome chemotherapeutic resistance and minimize side effects are under exploration.…”

The influence of HK2 blood group antigen on human B cell activation for ABOi-KT conditions

“…In addition, for further quantitative analysis the variation of blood group B antibody concentration, the mouse monoclonal to anti-blood group B antibody in reagent was detected as Eppler A et al [ 36 ] and Yawata K et al [ 37 ] reported with some modification. As a result, the protein with a molecular weight about 181.7 kDa was identified as mouse anti-human blood group B antibody with concentration 0.57 mg/ml in the reagent (Fig.…”